Vimarsana
Biggest News Aggregation in the World

Rare Pediatric News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rare Pediatric. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rare Pediatric Today - Breaking & Trending Today

Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) - Vimarsana News

Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Published: February 13, 2024

New Prescription Drug User Fee Act date of June 30, 2024 ...

Source: marketscreener.com
Related Topics:
United StatesState Of CaliforniaMedioambientalesy TecnolInvestigaciones EnergGaurav ShahEnfermedades RarasDrug AdministrationCalifornia Institute For Regenerative Medicine Grant NumberRocket Pharmaceuticals IncUniversity College LondonRocket PharmaceuticalsPriority ReviewBiologics License ApplicationLeukocyte Adhesion Deficiency IChief Executive OfficerMedicine Advanced TherapyRare PediatricFast TrackAdvanced Therapy Medicinal ProductOrphan DrugCentro De Investigaciones EnergCentro De InvestigaciRed De Enfermedades RarasInstituto De InvestigaciSanitaria Fundaci
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform - QSAM Biosciences (OTC:QSAM) - Vimarsana News

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform - QSAM Biosciences (OTC:QSAM)

Published: February 8, 2024

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (OTC:QSAM) and its

Source: benzinga.com
Related Topics:
United StatesUnited KingdomChristian BehrenbruchKyahn WilliamsonTelix Pharmaceuticals LimitedPharma IncBiosciences IncCorporate CommunicationsAustralian Securities ExchangeAustralian Therapeutic Goods AdministrationDrug AdministrationHealth CanadaIsotherapeutics GroupTelix PharmaceuticalsTelix Pharmaceuticals Limited BoardRare PediatricPriority Review VoucherManaging DirectorValue RightsListing RuleTerm SheetPharmaceuticals LimitedIncidence Of PatientsLarge Population BasedMetastatic Cancer Induced Bone Pain
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform - Vimarsana News

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

Published: February 7, 2024

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has ente...

Source: businessinsider.com
Related Topics:
United StatesUnited KingdomKyahn WilliamsonChristian BehrenbruchAustralian Therapeutic Goods AdministrationTelix PharmaceuticalsIsotherapeutics GroupDrug AdministrationPharma IncTelix Pharmaceuticals Limited BoardCorporate CommunicationsTelix Pharmaceuticals LimitedBiosciences IncHealth CanadaAustralian Securities ExchangePharmaceuticals LimitedRare PediatricPriority Review VoucherManaging DirectorValue RightsListing RuleTerm SheetIncidence Of PatientsLarge Population BasedMetastatic Cancer Induced Bone Pain
Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease - Vimarsana News

Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease

Published: May 31, 2023

Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today... | May 31, 2023

Source: marketscreener.com
Related Topics:
Kinnari PatelRocket Pharmaceuticals IncEuropean Medicines AgencyYork Heart AssociationRocket PharmaceuticalsPriority MedicinesDanon DiseaseRegenerative Medicine Advanced TherapyFast TrackOrphan DrugRare PediatricChief Operating OfficerEuropean RegulatoryNew York Heart AssociationKansas City CardiomyopathyFanconi AnemiaLeukocyte Adhesion Deficiency IPyruvate Kinase DeficiencyNc Stock ExchangePress ReleaseNmet Rckt Us77313f1066
Synlogic : Reports First Quarter 2023 Financial Results and Provides Business Update - Form 8-K - Vimarsana News

Synlogic : Reports First Quarter 2023 Financial Results and Provides Business Update - Form 8-K

Published: May 11, 2023

Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update - Phenylketonuria program on track for Phase 3 trial initiation in first half of 2023 - ... | May 11, 2023

Source: marketscreener.com
Related Topics:
United KingdomNew YorkUnited StatesAoife BrennanExchange CommissionSynlogic IncSociety For Inherited Metabolic DisordersDrug AdministrationEuropean Medicines AgencySynlogic Reports First QuarterProvides Business UpdateRare PediatricOrphan Drug DesignationsSynlogic PresidentChief ExecutiveSynthetic BioticsRecent Business HighlightsOrphan Drug DesignationRare Pediatric Disease DesignationInherited Metabolic DisordersSynthetic BioticIndustry Conference ParticipationJefferies Global Healthcare ConferenceGinkgo BioworksPrivate Securities Litigation Reform Act